2023 SUO Recaps : Episode 2

Commentary

Video

Dr. Kukreja on key kidney cancer research presented at SUO 2023

Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting.

In this video, Janet Kukreja, MD, outlines key kidney cancer research that was presented at this year’s Society of Urologic Oncology Annual Meeting, held in Washington DC. Kukreja is a urologic oncologist and an associate professor of surgery-urology at the University of Colorado in Aurora, CO. During the discussion, Kukreja touch on the following abstracts:

  • Poster 6: SWOG S1931 (PROBE): Phase III randomized trial of immune checkpoint inhibitor (ICI) combination regimen with or without cytoreductive nephrectomy (CN) in advanced renal cancer [NCT04510597] – Hyung Kim, MD
  • Poster 7: Safety of partial and radical nephrectomy for complex locally advanced renal cell carcinoma after neo-adjuvant immune checkpoint inhibition (durvalumab +/- tremelimumab) – Joseph Zabell, MD
  • Poster 101: Socioeconomic and demographic disparities in immunotherapy for advanced clear cell renal cell carcinoma – Levi Holland, MD
  • Poster 13: Limited utility of quantitative thresholds on 99MTC-sestamibi SPECT/CT for distinguishing renal cell carcinoma from oncocytic renal masses – Robert S. Wang, MD
  • Poster 103: Comprehensive Immunogenomic Evaluation of Patients Undergoing Consolidative Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Patients Treated with Immune Checkpoint Blockade – Stephen Reese, MD
Related Videos
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Pierre Blanchard, MD, PhD: What can hydrogel space provide to optimal prostate cancer care?
Savita Dandapani, MD, PhD: Findings from the phase 2 SHARP trial
Related Content
© 2024 MJH Life Sciences

All rights reserved.